News for Healthier Living
Targeting CDK2 Could Boost Immunotherapy Response in Patients with a Wide Range of Cancers, According to Dana-Farber Science
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.
September 3, 2026
September 8 2026September 7 2026September 5 2026September 4 2026September 3 2026September 2 2026September 1 2026August 31 2026August 30 2026August 29 2026August 28 2026August 27 2026August 26 2026August 25 2026
|
|
|
|
|